Hexarelin 5mg/vial 1 Vial by Master Pharma

Usage

1. Before reconstitution, verify the vial seal is intact and check Master Pharma's batch code against the HPLC release certificate supplied with the product.
2. Add 1–2 ml bacteriostatic water for injection slowly down the inner vial wall using a 23–25 gauge needle; allow lyophilised cake to dissolve without agitation — swirl gently only after full wetting.
3. Transfer reconstituted solution to a sterile insulin syringe; for a 100 mcg dose from a 1 ml / 5 mg solution, draw 0.02 ml (20 IU on a U-100 syringe).
4. Inject subcutaneously into abdominal or deltoid skin fold; rotate injection sites each session to avoid localised tissue irritation during the multi-week bridge period.
5. Time injections to fasted states (morning before breakfast, or 2 hours after the last meal of the day) to avoid insulin-mediated blunting of the GH pulse.
6. Store the reconstituted vial at 2–8 °C, protected from light; discard any unused solution after 28 days or if visible particulates appear.

Warnings

Frequently asked questions

Which peptides are suitable for a PCT bridge without suppressing testosterone recovery?

Hexarelin is suitable because it acts exclusively on GHS-R1a and CD36 receptors — neither of which is part of the HPG axis. It stimulates pulsatile GH release without signalling through androgen or estrogen receptors, so natural testosterone recovery through HPTA restoration proceeds unimpeded while GH-mediated anabolic support continues throughout the PCT window.

Do GH secretagogues like Hexarelin suppress your natural hormonal axis during PCT?

No. GHRP-class peptides including Hexarelin act on the somatotroph axis, not the hypothalamic-pituitary-gonadal axis. They do not suppress LH, FSH, or endogenous testosterone production. This receptor-pathway separation is precisely why Hexarelin is selected as a PCT-compatible agent when androgenic compounds have been discontinued and HPTA recovery is the primary goal.

How do you protect joints and connective tissue after an anabolic cycle using peptides?

Hexarelin supports joint health post-cycle by sustaining GH pulse amplitude, which drives IGF-1 elevation and downstream collagen synthesis in tendons and synovial tissue. Practitioners typically run 100–200 mcg per injection, two to three times daily, on a five-days-on/two-days-off schedule to maintain GHS-R1a sensitivity and continuous connective-tissue signalling throughout the bridge phase.

How do you reconstitute and store Master Pharma Hexarelin 5mg/vial after opening?

Reconstitute with 1–2 ml bacteriostatic water for injection using a 23–25 gauge needle directed against the vial wall; swirl gently — never vortex. Once reconstituted, refrigerate at 2–8 °C and use within 28 days. The 5 mg fill allows fine volume-based micro-dosing with an insulin syringe: 1 ml bacteriostatic water yields 5 mcg per 0.001 ml, enabling accurate sub-100 mcg doses.

Why choose a 5mg/vial Hexarelin format for a bridge protocol compared to higher-concentration vials?

The 5 mg/vial concentration is the smallest fill in this product group, which makes it ideal for precise dose titration during PCT when users often start conservatively — typically 100 mcg per injection — and adjust based on GH-response signs such as water retention or joint warmth. Smaller vials also reduce reconstituted-solution waste if the bridge period is shorter than anticipated, preserving peptide stability. (2) angle_used

Manufacturer

Cold-chain integrity is the operational cornerstone of Master Pharma's lyophilised peptide dispatch programme — a function that operates under documented storage protocols from primary manufacturing through final packaging. For Hexarelin vials, warehouse conditions are maintained at 2–8 °C in monitored refrigerated zones, with temperature-excursion logging applied throughout the holding period prior to shipment. Each outbound consignment is packed with validated cold-pack inserts rated for the declared transit duration, and internal audit records confirm that no vial lot is released for dispatch unless cold-chain continuity documentation is complete and unbroken. This infrastructure distinction matters particularly for a lyophilised hexapeptide where even brief ambient-temperature exposure above 25 °C during storage can accelerate degradation of the peptide backbone before the product reaches the end user.